Bellerophon Therapeutics (NASDAQ:BLPH – Get Rating) announced its quarterly earnings results on Wednesday. The biotechnology company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.04), MarketWatch Earnings reports.
Shares of NASDAQ BLPH traded up $0.02 during trading hours on Thursday, hitting $0.87. The company had a trading volume of 17,987 shares, compared to its average volume of 58,331. The stock has a market capitalization of $8.30 million, a P/E ratio of -0.47 and a beta of -0.17. Bellerophon Therapeutics has a 1-year low of $0.67 and a 1-year high of $5.95. The firm’s 50 day moving average is $1.89 and its 200-day moving average is $2.52.
An institutional investor recently bought a new position in Bellerophon Therapeutics stock. Millennium Management LLC acquired a new stake in Bellerophon Therapeutics, Inc. (NASDAQ:BLPH – Get Rating) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 24,134 shares of the biotechnology company’s stock, valued at approximately $75,000. Millennium Management LLC owned about 0.25% of Bellerophon Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 12.93% of the company’s stock.
Bellerophon Therapeutics Company Profile (Get Rating)
Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.
- Get a free copy of the StockNews.com research report on Bellerophon Therapeutics (BLPH)
- Carvana Insiders Buy Shares But Maybe You Shouldn’t
- Dutch Bros Gets Scalded By Inflation
- The S&P 500 Could Fall Another 28%
- Corning Stock is a Technology Value Play
- Wolverine Worldwide Is Ready To Rebound
Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.